60 - References

References

Depression and anxiety disorders CHAPTER 3 References

1. Satel SL, et al. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989; 50:241–249.
2. Warneke L. Psychostimulants in psychiatry. Can J Psychiatry 1990; 35:3–10.
3. Goss AJ, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-­analysis of randomized controlled trials. J Clin Psychiatry 2013; 74:1101–1107.
4. Candy M, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; (2):CD006722.
5. McIntyre RS, et  al. The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-­analysis. J Clin Psychopharmacol 2017; 37:412–418.
6. Bahji A, et al. Comparative efficacy and safety of stimulant-­type medications for depression: a systematic review and network meta-­analysis. J Affect Disord 2021; 292:416–423.
7. Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-­label pilot study. J Affect Disord 2004; 81:173–178.
8. Kaufman KR, et al. Modafinil monotherapy in depression. Eur Psychiatry 2002; 17:167–169.
9. Hegerl U, et al. Why do stimulants not work in typical depression? Aust N Z J Psychiatry 2017; 51:20–22.
10. Little KY. d-­Amphetamine versus methylphenidate effects in depressed inpatients. J Clin Psychiatry 1993; 54:349–355.
11. Robin AA, et al. A controlled trial of methylphenidate (ritalin) in the treatment of depressive states. J Neurol Neurosurg Psychiatry 1958; 21:55–57.
12. Lavretsky H, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 2003; 64:1410–1414.
13. Postolache TT, et al. Early augmentation of sertraline with methylphenidate. J Clin Psychiatry 1999; 60:123–124.
14. Gwirtsman HE, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacol Bull 1994; 30:157–164.
15. Giacobbe P, et al. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: a meta-­analysis of randomized controlled trials. J Affect Disord 2018; 226:294–300.
16. Fava M, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007; 19:153–159.
17. Kerr CW, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-­blind, placebo-­controlled trial. J Pain Symptom Manage 2012; 43:68–77.
18. Rasmussen NA, et al. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-­reported symptoms covered by the major depression inventory (MDI) and the symptom checklist (SCL-­92). Nord J Psychiatry 2005; 59:173–178.
19. DeBattista C, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004; 24:87–90.
20. Markovitz PJ, et  al. An open-­label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003; 23:207–209.
21. Ravindran AV, et al. Osmotic-­release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-­blind, randomized, placebo-­controlled trial. J Clin Psychiatry 2008; 69:87–94.
22. Ghanean H, et al. Fatigue in patients with major depressive disorder: prevalence, burden and pharmacological approaches to management. CNS Drugs 2018; 32:65–74.
23. Vaccarino SR, et al. The potential procognitive effects of modafinil in major depressive disorder: a systematic review. J Clin Psychiatry 2019; 80:19r12767.
24. Fawcett J, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment refractory depression. J Clin Psychopharmacol 1991; 11:127–132.
25. Israel JA. Combining stimulants and monoamine oxidase inhibitors: a reexamination of the literature and a report of a new treatment combination. Prim Care Companion CNS Disord 2015; 17:10.4088/PCC.4015br01836.
26. Rohde C, et al. The use of stimulants in depression: results from a self-­controlled register study. Aust N Z J Psychiatry 2020; 54:808–817.
27. Parker G, et al. Do the old psychostimulant drugs have a role in managing treatment-­resistant depression? Acta Psychiatr Scand 2010; 121:308–314.
28. Richards C, et al. A randomized, double-­blind, placebo-­controlled, dose-­ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. J Psychopharmacol 2017; 31:1190–1203.
29. Szmulewicz AG, et al. Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-­analysis. Acta Psychiatr Scand 2017; 135:527–538.
30. Perugi G, et al. Use of stimulants in bipolar disorder. Curr Psychiatry Rep 2017; 19:7.
31. Frye MA, et al. A placebo-­controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007; 164:1242–1249.
32. Tsapakis EM, et al. Adjunctive treatment with psychostimulants and stimulant-­like drugs for resistant bipolar depression: a systematic review and meta-­analysis. CNS Spectr 2020; doi: 10.1017/S109285292000156X.
33. Nunez NA, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-­analysis of randomized controlled trials. Bipolar Disord 2020; 22:109–120.
34. Chiorean A, et al. Prescribed psychostimulants and other pro-­cognitive medications in bipolar disorder: a systematic review and meta-­ analysis of recurrence of manic symptoms. Bipolar Disord 2024; 26:418–430.
35. Kwok WY, et al. High-­dose armodafinil in treatment-­refractory bipolar depression. Ann Clin Psychiatry 2023; 35:195–198.

392 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 36. Dell’Osso B, et al. Assessing the roles of stimulants/stimulant-­like drugs and dopamine-­agonists in the treatment of bipolar depression. Curr Psychiatry Rep 2013; 15:378. 37. McElroy SL, et  al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-­controlled trial. Int Clin Psychopharmacol 2015; 30:6–13. 38. Fernandez F, et al. Methylphenidate for depressive disorders in cancer patients. Psychosomatics 1987; 28:455–461. 39. Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998; 16:193–198. 40. Homsi J, et al. Methylphenidate for depression in hospice practice. Am J Hospice Palliat Care 2000; 17:393–398. 41. Sarhill N, et  al. Methylphenidate for fatigue in advanced cancer: a prospective open-­label pilot study. Am J Hosp Palliat Care 2001; 18:187–192. 42. Homsi J, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 2001; 18:403–407. 43. Burns MM, et al. Dextroamphetamine treatment for depression in terminally ill patients. Psychosomatics 1994; 35:80–83. 44. Olin J, et al. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996; 37:57–62. 45. Ng CG, et al. Rapid response to methylphenidate as an add-­on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-­week, randomized, double-­blinded, placebo-­controlled study. Eur Neuropsychopharmacol 2014; 24:491–498. 46. Sullivan DR, et al. Randomized, double-­blind, placebo-­controlled study of methylphenidate for the treatment of depression in SSRI-­treated cancer patients receiving palliative care. Psychooncology 2017; 26:1763–1769. 47. Conley CC, et  al. Modafinil moderates the relationship between cancer-­related fatigue and depression in 541 patients receiving ­chemotherapy. J Clin Psychopharmacol 2016; 36:82–85. 48. Padala PR, et  al. Methylphenidate for apathy in community-­dwelling older veterans with mild Alzheimer’s disease: a double-­blind, randomized, placebo-­controlled trial. Am J Psychiatry 2018; 175:159–168. 49. Kaplitz SE. Withdrawn, apathetic geriatric patients responsive to methylphenidate. J Am Geriatr Soc 1975; 23:271–276. 50. Jacobson A. The use of ritalin in psychotherapy of depressions of the aged. Psychiatr Q 1958; 32:474–483. 51. Wallace AE, et al. Double-­blind, placebo-­controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152:929–931. 52. Smith KR, et al. Methylphenidate use in geriatric depression: a systematic review. Int J Geriatr Psychiatry 2021; 36:1304–1312. 53. Grade C, et  al. Methylphenidate in early poststroke recovery: a double-­blind, placebo-­controlled study. Arch Phys Med Rehabil 1998; 79:1047–1050. 54. Lazarus LW, et al. Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry 1992; 53:447–449. 55. Lingam VR, et al. Methylphenidate in treating poststroke depression. J Clin Psychiatry 1988; 49:151–153. 56. Delbari A, et al. Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-­blind, placebo-­controlled trial. Eur Neurol 2011; 66:7–13. 57. Sugden SG, et al. Modafinil monotherapy in poststroke depression. Psychosomatics 2004; 45:80–81. 58. Rosenberg PB, et al. Methylphenidate in depressed medically ill patients. J Clin Psychiatry 1991; 52:263–267. 59. Woods SW, et al. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 1986; 47:12–15. 60. Kaufmann MW, et al. The use of d-­amphetamine in medically ill depressed patients. J Clin Psychiatry 1982; 43:463–464. 61. Wagner GJ, et al. Dexamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997; 42:407–411. 62. Wagner GJ, et al. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-­blind, placebo-­controlled trial. J Clin Psychiatry 2000; 61:436–440. 63. Cheng YS, et al. Therapeutic benefits of pharmacologic and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: a systematic review and network meta-­analysis. J Psychiatry Neurosci 2021; 46:e196–e207.